Expression of haem oxygenase-1 correlates with tumour aggressiveness and BRAFV600E expression in thyroid cancer

Histopathology

Volumn 66, Issue 3, 2015, Pages 447-456

  Wang, Tao Yeuan ^a,b   Liu, Chien Liang ^a,b   Chen, Ming Jen ^a,c   Lee, Jie Jen ^a,b,c   Pun, Pou Chu ^a   Cheng, Shih Ping ^a,b,c  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b NURSING AND MANAGEMENT COLLEGE   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

BRAF; Haem oxygenase 1; Immunohistochemistry; Thyroid cancer

Indexed keywords

B RAF KINASE; HEME OXYGENASE 1; BRAF PROTEIN, HUMAN; HMOX1 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; HUMAN TISSUE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID CANCER; TISSUE MICROARRAY; TUMOR INVASION; UPREGULATION; ADULT; BIOSYNTHESIS; FEMALE; GENETICS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PATHOLOGY; THYROID TUMOR; WESTERN BLOTTING;

ADULT; BLOTTING, WESTERN; FEMALE; HEME OXYGENASE-1; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84921491011     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12562     Document Type: Article

References (40)

1. American Thyroid Association Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19; 1167-1214.
2. Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat. Rev. Cancer 2013; 13; 184-199.
3. Brose MS, Nutting CM, Jarzab B et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014; 384; 319-328.
4. Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat. Rev. Endocrinol. 2011; 7; 569-580.
5. Cheng SP, Hsu YC, Liu CL et al. Significance of allelic percentage of BRAF c.1799T>A (V600E) mutation in papillary thyroid carcinoma. Ann. Surg. Oncol. 2014; doi:10.1245/s10434-014-3723-5.
6. Koperek O, Kornauth C, Capper D et al. Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. Am. J. Surg. Pathol. 2012; 36; 844-850.
7. Bullock M, O'Neill C, Chou A et al. Utilization of a MAB for BRAF(V600E) detection in papillary thyroid carcinoma. Endocr. Relat. Cancer 2012; 19; 779-784.
8. Ryter SW, Choi AM. Heme oxygenase-1/carbon monoxide: from metabolism to molecular therapy. Am. J. Respir. Cell Mol. Biol. 2009; 41; 251-260.
9. Jozkowicz A, Was H, Dulak J. Heme oxygenase-1 in tumors: is it a false friend? Antioxid. Redox Signal. 2007; 9; 2099-2117.
10. Chen GG, Liu ZM, Vlantis AC, Tse GM, Leung BC, van Hasselt CA. Heme oxygenase-1 protects against apoptosis induced by tumor necrosis factor-alpha and cycloheximide in papillary thyroid carcinoma cells. J. Cell. Biochem. 2004; 92; 1246-1256.
11. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A eds. AJCC cancer staging manual. 7th ed. New York, NY: Springer, 2010.
12. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993; 114; 1050-1057.
13. Liu CL, Cheng SP, Lin HW, Lai YL. Risk of thyroid cancer in patients with thyroiditis: a population-based cohort study. Ann. Surg. Oncol. 2014; 21; 843-849.
14. Cheng SP, Chi CW, Tzen CY et al. Clinicopathologic significance of leptin and leptin receptor expressions in papillary thyroid carcinoma. Surgery 2010; 147; 847-853.
15. Takahashi S, Takahashi Y, Ito K, Nagano T, Shibahara S, Miura T. Positive and negative regulation of the human heme oxygenase-1 gene expression in cultured cells. Biochim. Biophys. Acta 1999; 1447; 231-235.
16. Ning W, Song R, Li C et al. TGF-beta1 stimulates HO-1 via the p38 mitogen-activated protein kinase in A549 pulmonary epithelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 2002; 283; L1094-L1102.
17. Cheng SP, Liu CL, Hsu YC, Chang YC, Huang SY, Lee JJ. Expression and biologic significance of adiponectin receptors in papillary thyroid carcinoma. Cell Biochem. Biophys. 2013; 65; 203-210.
18. Chang YC, Hsu YC, Liu CL, Huang SY, Hu MC, Cheng SP. Local anesthetics induce apoptosis in human thyroid cancer cells through the mitogen-activated protein kinase pathway. PLoS ONE 2014; 9; e89563.
19. He H, Jazdzewski K, Li W et al. The role of microRNA genes in papillary thyroid carcinoma. Proc. Natl Acad. Sci. USA 2005; 102; 19075-19080.
20. Hebrant A, Dom G, Dewaele M et al. mRNA expression in papillary and anaplastic thyroid carcinoma: molecular anatomy of a killing switch. PLoS ONE 2012; 7; e37807.
21. Was H, Dulak J, Jozkowicz A. Heme oxygenase-1 in tumor biology and therapy. Curr. Drug Targets 2010; 11; 1551-1570.
22. Degese MS, Mendizabal JE, Gandini NA et al. Expression of heme oxygenase-1 in non-small cell lung cancer (NSCLC) and its correlation with clinical data. Lung Cancer 2012; 77; 168-175.
23. Becker JC, Fukui H, Imai Y et al. Colonic expression of heme oxygenase-1 is associated with a better long-term survival in patients with colorectal cancer. Scand. J. Gastroenterol. 2007; 42; 852-858.
24. Berberat PO, Dambrauskas Z, Gulbinas A et al. Inhibition of heme oxygenase-1 increases responsiveness of pancreatic cancer cells to anticancer treatment. Clin. Cancer Res. 2005; 11; 3790-3798.
25. Nowis D, Legat M, Grzela T et al. Heme oxygenase-1 protects tumor cells against photodynamic therapy-mediated cytotoxicity. Oncogene 2006; 25; 3365-3374.
26. Hirai K, Sasahira T, Ohmori H, Fujii K, Kuniyasu H. Inhibition of heme oxygenase-1 by zinc protoporphyrin IX reduces tumor growth of LL/2 lung cancer in C57BL mice. Int. J. Cancer 2007; 120; 500-505.
27. Schweppe RE, Klopper JP, Korch C et al. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J. Clin. Endocrinol. Metab. 2008; 93; 4331-4341.
28. Nielsen VG, Garol BD, Zelman EA, Guerrero MA. Hemeoxygenase-1 mediated hypercoagulability in a patient with thyroid cancer. Blood Coagul. Fibrinolysis 2013; 24; 663-665.
29. Do MT, Kim HG, Khanal T et al. Metformin inhibits heme oxygenase-1 expression in cancer cells through inactivation of Raf-ERK-Nrf2 signaling and AMPK-independent pathways. Toxicol. Appl. Pharmacol. 2013; 271; 229-238.
30. Klubo-Gwiezdzinska J, Costello J Jr, Patel A et al. Treatment with metformin is associated with higher remission rate in diabetic patients with thyroid cancer. J. Clin. Endocrinol. Metab. 2013; 98; 3269-3279.
31. Willis D, Moore AR, Frederick R, Willoughby DA. Heme oxygenase: a novel target for the modulation of the inflammatory response. Nat. Med. 1996; 2; 87-90.
32. Niimi M, Takashina M, Takami H et al. Overexpression of heme oxygenase-1 protects allogeneic thyroid grafts from rejection in naive mice. Surgery 2000; 128; 910-917.
33. Poss KD, Tonegawa S. Heme oxygenase 1 is required for mammalian iron reutilization. Proc. Natl Acad. Sci. USA 1997; 94; 10919-10924.
34. McDaid J, Yamashita K, Chora A et al. Heme oxygenase-1 modulates the allo-immune response by promoting activation-induced cell death of T cells. FASEB J. 2005; 19; 458-460.
35. Andersen MH, Sorensen RB, Brimnes MK, Svane IM, Becker JC, thor Straten P. Identification of heme oxygenase-1-specific regulatory CD8+ T cells in cancer patients. J. Clin. Invest. 2009; 119; 2245-2256.
36. Li C, Lee KC, Schneider EB, Zeiger MA. BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J. Clin. Endocrinol. Metab. 2012; 97; 4559-4570.
37. Nucera C, Porrello A, Antonello ZA et al. B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc. Natl Acad. Sci. USA 2010; 107; 10649-10654.
38. Couto JP, Daly L, Almeida A et al. STAT3 negatively regulates thyroid tumorigenesis. Proc. Natl Acad. Sci. USA 2012; 109; E2361-E2370.
39. Tron K, Samoylenko A, Musikowski G et al. Regulation of rat heme oxygenase-1 expression by interleukin-6 via the Jak/STAT pathway in hepatocytes. J. Hepatol. 2006; 45; 72-80.
40. Ilie MI, Lassalle S, Long-Mira E et al. Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays. Thyroid 2014; 24; 858-866.